Shares of Soleno Therapeutics (NASDAQ: SLNO) are surging in pre-market trading on Thursday, climbing 7.17% following a series of bullish analyst updates. The biotechnology company's stock is reacting positively to multiple price target increases and maintained positive ratings from Wall Street analysts.

Leading the charge, Guggenheim raised its target price for Soleno from $81 to $97, signaling strong confidence in the company's future prospects. This significant upward revision was followed by Stifel Nicolaus analyst James Condulis, who maintained a Buy rating on Soleno Therapeutics with a price target of $108. Additionally, Baird reiterated its Outperform rating on the stock.

While specific reasons for the analysts' more optimistic outlook were not immediately available, such target price increases are typically based on factors like improved financial performance, promising drug development progress, or positive industry trends. The consensus bullish stance from multiple analysts suggests a growing confidence in Soleno Therapeutics' potential, driving investor interest and contributing to the stock's pre-market surge. As always, investors are advised to conduct their own research and consider their individual risk tolerance before making investment decisions based on analyst recommendations.